Skip to main content

Table 2 Overall and stratified risk estimates of three lipid derivatives for gastric cancer mortality in both derivation and validation groups

From: Prediction of three lipid derivatives for postoperative gastric cancer mortality: the Fujian prospective investigation of cancer (FIESTA) study

Characteristics Subgroups Derivation group (n = 1506) Validation group (n = 1506)
AI THR LHR AI THR LHR
Overall Unadjusted 1.28, 1.22–1.35, < 0.001 1.19, 1,14–1.24, < 0.001 1.24, 1.19–1.30, < 0.001 1.32, 1.23–1.41, < 0.001 1.21, 1.13–1.29, < 0.001 1.29, 1.21–1.38, < 0.001
Overall Adjusted 1.20, 1.13–1.26, < 0.001 1.17, 1.11–1.24, < 0.001 1.19, 1.13–1.25, < 0.001 1.27, 1.17–1.37, < 0.001 1.16, 1.08–1.24, < 0.001 1.24, 1.15–1.35, < 0.001
Gender Male 1.27, 1.17–1.38, < 0.001 1.18, 1.11–1.26, < 0.001 1.25, 1.15–1.36, < 0.001 1.30, 1.18–1.43, < 0.001 1.17, 1.08–1.27, < 0.001 1.26, 1.16–1.38, < 0.001
Female 1.16, 1.06–1.26, 0.001 1.17, 1.03–1.33, 0.019 1.19, 1.10–1.29, < 0.001 1.26, 1.06–1.48, 0.012 1.12, 0.97–1.29, 0.136 1.17, 0.96–1.42, 0.118
Smoking Ever 1.15, 0.90–1.47, 0.133 1.14, 1.05–1.24, 0.011 1.14, 0.90–1.45, 0.270 1.08, 0.90–1.31, 0.397 1.04, 0.87–1.24, 0.649 1.09, 0.90–1.31, 0.381
Never 1.22, 1.13–1.32, < 0.001 1.18, 1.07–1.29, < 0.001 1.23, 1.15–1.34, < 0.001 1.29, 1.18–1.42, < 0.001 1.18, 1.10–1.27, < 0.001 1.29, 1.18–1.40, < 0.001
TNM stage I-II 1.59, 1.34–1.87, < 0.001 1.29, 1.17–1.42, < 0.001 1.67, 1.38–2.01, < 0.001 1.38, 1.12–1.69, 0.002 1.17, 0.84–1.62, 0.351 1.34, 1.09–1.65, 0.005
III-IV 1.19, 1.13–1.27, < 0.001 1.18, 1.11–1.26, < 0.001 1.17, 1.10–1.23, < 0.001 1.26, 1.16–1.37, < 0.001 1.18, 1.09–1.27, < 0.001 1.24, 1.14–1.35, < 0.001
Lauren’s classification Intestinal type 1.36, 1.18–1.57, < 0.001 1.27. 1.12–1.44, < 0.001 1.29, 1.11–1.51, 0.001 1.42, 1.20–1.66, < 0.001 1.21, 1.11–1.32, < 0.001 1.34, 1.14–1.58, < 0.001
Diffuse type 1.19, 1.12–1.27, < 0.001 1.16, 1.07–1.26, < 0.001 1.17, 1.10–1.24, 0.001 1.13, 1.04–1.22, 0.003 1.12, 1.05–1.23, 0.003 1.16, 1.06–1.27, 0.001
Tumor embolus Positive 1.23, 1.13–1.35, < 0.001 1.23, 1.14–1.33, < 0.001 1.28, 1.15–1.42, < 0.001 1.29, 1.15–1.44, < 0.001 1.16, 1.04–1.28, 0.006 1.27, 1.13–1.43, < 0.001
Negative 1.17, 1.09–1.26, < 0.001 1.11, 1.03–1.21, 0.011 1.16, 1.08–1.23, < 0.001 1.25, 1.12–1.40, < 0.001 1.16, 1.06–1.28, 0.002 1.22, 1.09–1.37, 0.001
Obesity With 1.11, 1.04–1.19, 0.031 1.13, 1.03–1.24, 0.012 1.09, 1.00–1.19, 0.051 1.12, 1.01–1.22, 0.042 1.07, 0.95–1.20, 0.276 1.07, 0.91–1.26, 0.399
Without 1.26, 1.10–1.43, 0.001 1.18, 1.10–1.26, < 0.001 1.24, 1.09–1.40, 0.001 1.31, 1.20–1.43, < 0.001 1.21, 1.11–1.32, < 0.001 1.30, 1.18–1.42, < 0.001
Hypertension With 1.07, 0.94–1.22, 0.338 1.05, 0.92–1.19, 0.502 1.08, 0.94–1.24, 0.271 1.17, 1.01–1.35, 0.037 1.14, 1.00–1.29, 0.045 1.15, 0.98–1.35, 0.096
Without 1.22, 1.15–1.30, < 0.001 1.21, 1.14–1.28, < 0.001 1.21, 1.14–1.28, < 0.001 1.30, 1.18–1.42, < 0.001 1.16, 1.07–1.26, 0.001 1.27, 1.16–1.39, < 0.001
Diabetes With 1.13, 1.04–1.22, 0.004 1.08, 1.02–1.16, 0.013 1.14, 1.05–1.25, 0.001 1.17, 1.08–1.28, 0.002 1.07, 0.98–1.16, 0.106 1.18, 1.08–1.29, < 0.001
Without 1.18, 1.07–1.29, 0.001 1.16, 0.98–1.36, 0.080 1.15, 1.06–1.26, 0.001 1.21, 1.08–1.36, < 0.001 1.20, 1.05–1.38, 0.010 1.20, 1.09–1.30, < 0.001
  1. Data are expressed as hazard ratio, 95% confidence interval, P value. Besides unadjusted overall estimates, the other risk estimates were calculated after adjusting for age, gender, smoking, drinking, family cancer history, body mass index, systolic blood pressure, diastolic blood pressure, fasting blood glucose, TNM stage, tumor size, Lauren’s classification, number of lymph node metastasis and tumor embolus by removing the characteristic itself in stratified analysis
  2. Abbreviations: AI atherogenic index, THR the triglyceride to high-density lipoprotein cholesterol ratio, LHR the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio, TNM tumor-node-metastasis